Expansion Opportunity IBA is actively expanding its proton therapy footprint, including first proton therapy center installation in Brazil. This signals ongoing demand for Proteus systems and related services in new markets, representing cross-border sales opportunities for turnkey proton therapy solutions, installation, and long-term maintenance contracts.

Strategic Partnerships Recent collaborations with healthcare and pharmaceutical entities for cyclotron systems (Telix partnership for four Cyclone KIUBE units) indicate a strong channel for modular production capabilities and radiopharmacy services, suggesting opportunities to upsell additional cyclotron capacity, service agreements, and turnkey radiopharmacy production solutions.

Diversified Portfolio IBA’s leadership across proton therapy, industrial sterilization, radiopharmaceuticals, and dosimetry opens cross-selling avenues to existing customers’ adjacent needs, including upgrades to therapy centers, sterilization applications, dosimetry systems, and companion radiopharmacy workflows.

Financial Strength With a revenue range and ongoing dividend signaling financial stability, there is room to pursue large-scale project financing, extended payment terms, or bundled deals for hospital networks and imaging centers seeking long-term capital expenditure plans.

Sustainability Edge As a certified B Corporation, IBA’s commitment to social and environmental performance can be leveraged to target sustainability-minded hospitals and research institutions, offering greener procurement programs, energy-efficient accelerator solutions, and responsible sourcing initiatives aligned with RFP requirements.